Prognostic value of CD4⁺ in patients with Т1-2N0M0 breast cancer

• Egile Nagusiak: R. M. Paltuev (Egilea), A. G. Kudaybergenova (Egilea), V. F. Semiglazov (Egilea), A. V. Komyakhov (Egilea), A. I. Tseluyko (Egilea)
• Formatua: Liburua
• Argitaratua: ABV-press, 2023-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Aim. To evaluate the prognostic value of CD4+ in patients with T1-2N0M0 breast cancer.Materials and methods. We performed a quantitative assessment of CD4+ T-lymphocytes in tumor stromal cells and determined the prognostic parameter using the method developed by us (patent No. RU2697709C1 dated 19.0...